The U.S. Food and Drug Administration lifted a clinical hold on Biomea Fusion's ongoing studies of its experimental drug for ...
They called their experimental drug KarXT, and shepherded it through clinical trials to prove its safety and effectiveness.
Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.
After years of pressure, the FDA said it is strengthening its review of many chemical additives used to enhance color, ...
The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of ...
An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...
The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food and ...
Broad Leib, a clinical professor of law at Harvard Law School, said the FDA should require that manufacturers share all new ...
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...
Biocompatibility and Toxicology Program published a statement announcing its intention to commission an independent literature review and internal bench laboratory study to evaluate the presence of ...
The FDA is set to make a pivotal decision Sept. 26 about KarXT, a novel antipsychotic developed by Karuna Therapeutics. If approved, it would be the first drug with a unique mechanism for treating ...